The oligoclonal therapeutic consists of a mixture of three fully human monoclonal antibodies which are designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
Adimab’s three lead antibodies and a number of backups were licensed exclusively to Merrimack.
Adimab CEO Tillman Gerngross said they launched their platform two and a half years ago and are now seeing the first programs enter the clinic.
"Merrimack had a validated target and an understanding of the biology necessary for a novel antibody therapeutic," Gerngross added.